The Texas law firm of Hilliard Munoz Gonzales, LLP is representing a number of individuals who have been injured or had loved ones die after taking part in the clinical trial for Bristol Myers-Squibb’s hepatitis C drug BMS-986094 (formerly known as INX-189). The drug has caused debilitating side effects, including heart or liver damage.

“In August 2012, Bristol Myers-Squibb sent out a letter to patients in the study warning about the alleged dangers of the drug. The letter stated the company was asking patients to discontinue use of the experimental drug due to a, ‘significant unexpected safety finding recently observed in participants who received study medication,’” said Bob Hilliard of Hilliard Muñoz Gonzales, LLP. “For many of our other clients, this letter was sent too late.”

About BMS-986094:
This drug is an investigational nucleotide polymerase inhibitor for the treatment of hepatitis C. Bristol Myers-Squibb discontinued development of it during the Phase II clinical trials in August 2012. Hepatitis C is a liver-destroying virus that infects more than 3 million people in the United States.

Experienced trial attorneys with years of experience handling pharmaceutical cases, Hilliard Muñoz Gonzales, LLP is representing individuals around the country that took part in the clinical trial for BMS-986094. If you or a loved one have been hospitalized due to BMS- 986094, call (361) 882-1612 today!